1 week Ago By Defense World Staff
Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) has been given an average rating of “Hold” by the nine research firms that are covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company.
The average 12-month price objective among analysts that have covered the stock in the last year is $8.39. A number of analysts have weighed in on the company.
Barclays reduced their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Monday, December 23rd.
Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Finally, StockNews.com began coverage on shares of Revance Therapeutics in a research note on Friday.
They issued a “hold” rating on the stock.Get Our Latest Stock Report on Revance TherapeuticsRevance Therapeutics Stock PerformanceRVNC opened at $3.65 on Friday.
The stock’s 50 day moving average price is $3.65 and its 200-day moving average price is $3.98.
Revance Therapeutics has a one year low of $2.30 and a one year high of $6.65.
The stock has a market cap of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.
90. Institutional Investors Weigh In On Revance TherapeuticsSeveral large investors have recently modified their holdings of the business. Oddo BHF Asset Management Sas purchased a new position in Revance Therapeutics during the third quarter valued at approximately $3,763,000.
FNY Investment Advisers LLC boosted its position in Revance Therapeutics by 160.4% during the 4th quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock valued at $1,452,000 after acquiring an additional 294,323 shares in the last quarter.
Wellington Management Group LLP purchased a new position in shares of Revance Therapeutics in the 3rd quarter valued at $2,315,000. Charles Schwab Investment Management Inc. raised its position in shares of Revance Therapeutics by 5.
5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 790,837 shares of the biopharmaceutical company’s stock worth $4,104,000 after acquiring an additional 41,250 shares in the last quarter.
Finally, State Street Corp lifted its stake in shares of Revance Therapeutics by 6.6% during the 3rd quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock worth $12,632,000 after purchasing an additional 150,323 shares during the last quarter.
Institutional investors own 97.70% of the company’s stock. Revance Therapeutics Company Profile (Get Free ReportRevance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.Featured StoriesFive stocks we like better than Revance TherapeuticsHow Can Retail Investors Trade the Toronto Stock Exchange (TSX)?Joby Aviation: Operational Momentum vs. Market SentimentWhat Are the FAANG Stocks and Are They Good Investments?Broadcom’s Big Outperformance Shows Strength Amid Tariff DeclineHow to invest in marijuana stocks in 7 steps Carvana: Can Turnaround Strength Outdrive Market Headwinds?.
